EMA allows emergency use of MSD's Covid-19 capsule treatment
MSD's capsule should be taken as early as possible after a Covid-19 diagnosis, within five days of symptoms beginning, the EMA instructs.
by RITZAU/AFP, translated by daniel pedersen
As Covid-19 cases soar in many places throughout Europe, the European Medicines Agency (EMA) has issued advice on Friday pertaining to the emergency use of MSD's Covid-19 capsule molnupiravir.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
EMA to investigate Covid-19 treatment
For subscribers
Denmark donates 250,000 Covid-19 vaccines to Rwanda
For subscribers
